These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 2732120)

  • 1. In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc B; Gooch G; Ho DH; Bodey GP
    J Antimicrob Chemother; 1989 Mar; 23(3):363-71. PubMed ID: 2732120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc B; Ho DH; Bodey GP
    J Antimicrob Chemother; 1990 Jul; 26(1):39-44. PubMed ID: 2211445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1990; 36(5):365-72. PubMed ID: 2209169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
    Dholakia N; Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Antimicrob Agents Chemother; 1994 Apr; 38(4):848-52. PubMed ID: 8031057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria.
    Hoban D; Grabowski M; Koss J; Weselowski V
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):77S-82S. PubMed ID: 2791502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
    Rolston KV; Nguyen H; Messer M; LeBlanc B; Ho DH; Bodey GP
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2263-6. PubMed ID: 2127348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL; Fuchs PC; Brown SD
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Gooch G; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):684-6. PubMed ID: 3143585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.
    Rolston K; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1988; 34(6):448-54. PubMed ID: 3149568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro evaluation of lomefloxacin].
    Dette GA; Knothe H
    Arzneimittelforschung; 1989 Aug; 39(8):832-5. PubMed ID: 2818672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
    Tanaka M; Yamazaki E; Chiba M; Yoshihara K; Akasaka T; Takemura M; Sato K
    Antimicrob Agents Chemother; 2002 Mar; 46(3):904-8. PubMed ID: 11850285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of T-3761, a new fluoroquinolone.
    Muratani T; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2293-303. PubMed ID: 1332594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.
    Prosser BL; Beskid G
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):33-45. PubMed ID: 7789095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antibacterial activity of the new quinolone Bay y3118 against clinical isolates.
    Ravizzola G; Pizzi R; Pirali F; Turano A
    J Chemother; 1994 Dec; 6(6):392-8. PubMed ID: 7699426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temafloxacin: in vitro comparison with five other antibacterial agents.
    Digranes A; Hardardottir H; Bottolfsen KL
    Chemotherapy; 1991; 37(2):98-105. PubMed ID: 2032475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.
    Bongaerts GP; Hoogkamp-Korstanje JA
    Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of lomefloxacin (SC 47111 or NY-198), a new quinolone antimicrobial, against clinical isolates of common pathogens.
    Sonstein SA; Dahlgren J
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):21S-28S. PubMed ID: 2791494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.